Stock listing

Revive Therapeutics Ltd.

Selected listing: A2AP4F · LSX · EUR · DE

Revive Therapeutics Ltd. (LS Exchange: A2AP4F), Health Technology. Latest release Sep 15, 2026: Revive Therapeutics to Expand Bucillamine IP and Orphan Drug…

A2AP4F:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A2AP4F
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

Latest news from Revive Therapeutics Ltd.

Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases

September 15, 2026

Revive Therapeutics Announces Proposed Shares for Debt Settlement

August 19, 2026

Revive Therapeutics Reports Grant of Options

August 14, 2026

Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

August 12, 2026

Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

July 15, 2026

All Revive Therapeutics Ltd. news →

Research Revive Therapeutics Ltd.

Revive Therapeutics Ltd. company profile

View the public company page for Revive Therapeutics Ltd. on 6ix.

Revive Therapeutics Ltd. news

Read company news and market updates connected to Revive Therapeutics Ltd..

Revive Therapeutics Ltd. investor events

Find investor webinars, events, and replay context for Revive Therapeutics Ltd..